MolDX: Molecular Diagnostic Tests (MDT)
J15 · Effective Oct 1, 2015
22 active Medicare policies list 87999, and 6 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Apr 17, 2022
JE · Effective Apr 17, 2022
6 policies from 6 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of 87999 |
|---|---|---|
| Metagenomic Sequencing for Infectious Disease in the Outpatient Setting | Oct 1, 2026 | Not covered |
| Policy | Effective | Status of 87999 |
|---|---|---|
| Reproductive Techniques and Immunotherapy for Recurrent Fetal Loss | Jan 1, 2026 | Covered |
| Policy | Effective | Status of 87999 |
|---|---|---|
| Reproductive Techniques and Immunotherapy for Recurrent Fetal Loss | Jan 1, 2026 | Covered |
JF · Effective Apr 17, 2022
JJ · Effective Apr 17, 2022
JM · Effective Apr 17, 2022
J5 · Effective Apr 17, 2022
J8 · Effective Apr 17, 2022
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
J5 · Effective Jul 1, 2026
National · Effective Aug 6, 2026
National · Effective Aug 6, 2026
National · Effective May 14, 2026
J5 · Effective Aug 6, 2026
| Policy | Effective | Status of 87999 |
|---|---|---|
| Reproductive Techniques and Immunotherapy for Recurrent Fetal Loss | Jan 1, 2026 | Covered |
| Policy | Effective | Status of 87999 |
|---|---|---|
| Reproductive Techniques and Immunotherapy for Recurrent Fetal Loss | Jan 1, 2026 | Covered |
| Policy | Effective | Status of 87999 |
|---|---|---|
| In Vitro Chemoresistance and Chemosensitivity Assays | Apr 1, 2026 | Covered |